Get the Stockscreener App
3.50
0.00%
0.00
After Hours:
3.51
0.010
+0.29%
Cyclerion Therapeutics Inc stock is traded at $3.50, with a volume of 15,802.
It is up +0.00% in the last 24 hours and up +3.55% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$3.50
Open:
$3.41
24h Volume:
15,802
Relative Volume:
0.33
Market Cap:
$15.16M
Revenue:
$1.99M
Net Income/Loss:
$-5.28M
P/E Ratio:
-2.5497
EPS:
-1.3727
Net Cash Flow:
$-3.59M
1W Performance:
-4.11%
1M Performance:
+3.55%
6M Performance:
+133.33%
1Y Performance:
+22.38%
1-Day Range:
$3.41
$3.55
1-Week Range:
$3.4021
$3.80
52-Week Range:
$1.0266
$8.48
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
3.50 | 15.16M | 1.99M | -5.28M | -3.59M | -1.3727 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cyclerion Therapeutics, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Cyclerion Therapeutics Inc (CYCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cyclerion Therapeutics, Inc. Revenue Breakdown – NASDAQ:CYCN - TradingView
TradingKey - TradingKey
Cyclerion Therapeutics Inc (CYCN) Institutional Confidence - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.370|Chg%:-0.130 - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.440|Chg%:-0.060 - TradingKey
Cyclerion Therapeutics Inc (CYCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.475|Chg%:-0.025 - TradingKey
Cyclerion Therapeutics Inc (CYCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RKLBRocket Lab Stock Price Today, News, Analysis and Trading Ideas - Stocktwits
Cyclerion Therapeutics (CYCN) plans merger with Korsana and $380M financing - Stock Titan
Form 13D/A CYCLERION THERAPEUTICS For: 21 July By Investing.com - Investing.com South Africa
Cyclerion Therapeutics (CYCN) investor reports 19.4% stake and preferred share conversion - Stock Titan
Cyclerion Therapeutics (CYCN) director converts 351,037 preferred to common shares - Stock Titan
Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beats Estimates as Pre-Revenue Biotech Tightens Cost ControlProfit Recovery Report - dars.gov.et
Cyclerion Therapeutics (CYCN) Retreats 1.9% as Stock Tests Crucial Support ZoneIV Spike - dars.gov.et
Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana in $380M financing deal - Stock Titan
Cyclerion Therapeutics to merge with Korsana Biosciences (KRSA) after $380M pre-closing financing - Stock Titan
Cyclerion Therapeutics (CYCN) Presses Lower: Support Test in FocusETF Creation Redemption - dars.gov.et
Cyclerion Therapeutics (CYCN) Gains 6.6% as Shares Test Key Resistance Near $3.55PCR Spike - dars.gov.et
Enterprise value to revenue forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Price to sales forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics,Inc. Actuals & Estimates (NASDAQ:CYCN) - TradingView
Cyclerion Therapeutics (CYCN) Faces Resistance as Shares Slide Nearly 4%Put Support - dars.gov.et
Cyclerion Therapeutics (CYCN) Edges Higher as Stock Tests Key ResistanceTriple MA Cross - DonanımHaber
Cyclerion Therapeutics Inc (CYCN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cyclerion Therapeutics Inc (CYCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cyclerion Therapeutics Inc (CYCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cyclerion Therapeutics, Inc. announced that it has received $200 million in funding - marketscreener.com
Cyclerion Therapeutics (CYCN) Hovers Near $3.00 as Low Volume Caps MovementDark Pool Volume - newsline.com
Cyclerion (NASDAQ: CYCN) to Merge with Korsana, $380M Pre-Closing Financing - Stock Titan
CYCN Q4 2025 Earnings: Narrowed Loss Surpasses Estimates Amid Pipeline ProgressEarnings Outlook Update - newsline.com
Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing - MSN
Cyclerion Therapeutics (CYCN) Edges Higher Amid Quiet TradingCash Flow Strong Stocks - The Legal Advocate
CYCN Q4 2025 Earnings: Narrowed Losses Exceed Expectations as Development Programs ProgressPre-Earnings Drift - The Legal Advocate
RKTO Stock Price and Chart — NASDAQ:RKTO - TradingView
Cyclerion Therapeutics Company Profile & Introduction - Moomoo
CYCN - Finviz
Cyclerion Therapeutics (CYCN) Edges Higher as Shares Test Key Resistance LevelsRounding Bottom - The Legal Advocate
Cyclerion Shares to Watch With Deal in Focus as Markets Reopen - Bez Kabli
CYCN Q4 2025 Earnings: Narrowed Loss Beats Street Estimates, Shares ClimbAnnual Report - newsline.com
Cyclerion (CYCN) Delivers Q4 2025 Beat — EPS $-0.21 vs $-0.39 ExpectedTangible Book Value - newsline.com
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
CYCN News | CYCLERION THERAPEUTICS INC (NASDAQ:CYCN) - ChartMill
Why Cyclerion (CYCN) deserves a deeper look right now (-2.78%) 2026-05-07Insider Info - newser.com
FMR LLC holds 15.0% of Cyclerion Therapeutics (NASDAQ: CYCN) in Schedule 13G - Stock Titan
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? - Sahm
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):